Provided by Tiger Trade Technology Pte. Ltd.

Acurx Pharmaceuticals, LLC*

1.42
+0.01000.71%
Volume:3K
Turnover:4.61K
Market Cap:7.77M
PE:-0.47
High:1.43
Open:1.41
Low:1.41
Close:1.41
52wk High:8.34
52wk Low:1.31
Shares:5.47M
Float Shares:5.34M
Volume Ratio:1.50
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0454
EPS(LYR):-5.3153
ROE:-128.11%
ROA:-55.92%
PB:0.95
PE(LYR):-0.27

Loading ...

Company Profile

Company Name:
Acurx Pharmaceuticals, LLC*
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
- -
Office Location:
259 Liberty Avenue,Staten Island,New York,United States
Zip Code:
10305
Fax:
- -
Introduction:
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Directors

Name
Position
David P. Luci
Chief Executive Officer,Director and President
Robert J. DeLuccia
Director and Executive Chairman
Carl V. Sailer
Independent Director
Jack H. Dean
Independent Director
James Donohue
Independent Director
Joseph C. Scodari
Independent Director
Thomas Harrison
Independent Director

Shareholders

Name
Position
David P. Luci
Chief Executive Officer,Director and President
Robert Shawah
Chief Financial Officer
Robert J. DeLuccia
Director and Executive Chairman